The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1440
April 14, 2014
View Complete Issue         Table of Contents 2019 
Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia
April 14, 2014 (Issue: 1440)
The FDA has approved ibrutinib (eye broo' ti nib; Imbruvica – Janssen/Pharmacyclics), an oral kinase inhibitor, for second-line treatment of chronic lymphocytic leukemia (CLL). It is the first kinase inhibitor to be approved for CLL. Ibrutinib...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia
Article code: 1440a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.